Harvard Bioscience (HBIO) Current Assets (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Current Assets data on file, last reported at $47.5 million in Q1 2026.

• On a quarterly basis, Current Assets rose 5.74% year-over-year to $47.5 million in Q1 2026; TTM through Mar 2026 was $47.5 million, a 5.74% increase from a year earlier, with the FY2025 full-year figure at $48.2 million, up 6.89% from the prior year.
• Current Assets for Q1 2026 stood at $47.5 million, down from $48.2 million in the prior quarter.
• Over the last five years, Current Assets for HBIO reached as high as $59.4 million in Q1 2022 and fell as low as $43.8 million in Q3 2025.
• Historically, Current Assets has averaged $49.4 million across 5 years, with a median of $48.2 million in 2025.
• On a YoY basis, Current Assets climbed as much as 20.77% in 2022 and fell as far as 16.98% in 2022.
• Year by year, Current Assets stood at $51.1 million in 2022, then slipped by 4.08% to $49.0 million in 2023, then decreased by 8.0% to $45.1 million in 2024, then climbed by 6.89% to $48.2 million in 2025, then fell by 1.55% to $47.5 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $47.5 million in Q1 2026, $48.2 million in Q4 2025, and $43.8 million in Q3 2025.